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ABSTRACT
Unlike classic gonadotropin-releasing hormone 1 (GNRH1),
the second mammalian isoform (GNRH2) is an ineffective
stimulant of gonadotropin release. Species that produce GNRH2
may not maintain a functional GNRH2 receptor (GNRHR2) due
to coding errors. A full-length GNRHR2 gene has been identified
in swine, but its role in reproduction requires further elucida-
tion. Our objective was to examine the role of GNRH2 and
GNRHR2 in testicular function of boars. We discovered that
GNRH2 levels were higher in the testis than in the anterior
pituitary gland or hypothalamus, corresponding to greater
GNRHR2 abundance in the testis versus the anterior pituitary
gland. Moreover, GNRH2 immunostaining was most prevalent
within seminiferous tubules, whereas GNRHR2 was detected in
high abundance on Leydig cells. GNRH2 pretreatment of testis
explant cultures elicited testosterone secretion similar to that of
human chorionic gonadotropin stimulation. Treatment of
mature boars with GNRH2 elevated testosterone levels similar
to those of GNRH1-treated males, despite minimal GNRH2-
induced release of luteinizing hormone (LH). When pretreated
with a GNRHR1 antagonist (SB-75), subsequent GNRH2
treatment stimulated low levels of testosterone secretion despite
a pattern of LH release similar to that in the previous trial,
suggesting that SB-75 inhibited testicular GNRHR2s. Given that
pigs lack testicular GNRHR1, these data may indicate that
GNRH2 and its receptor are involved in autocrine or paracrine
regulation of testosterone secretion. Notably, our data are the
first to suggest a biological function of a novel GNRH2-GNRHR2
system in the testes of swine.
GNRH2, GNRHR2, porcine, testis, testosterone
INTRODUCTION
The classic form of gonadotropin-releasing hormone 1
(GNRH1) is regarded as the master modulator of reproduction,
stimulating synthesis and secretion of the gonadotropins,
luteinizing hormone (LH), and follicle stimulating hormone
(FSH). Although GNRH1 conventionally regulates gonadotro-
pin secretion [1], it has also been ascribed extrapituitary
functions [2]. Both GNRH1 and its receptor (GNRHR1) have
been detected in mammalian testes [3–8], and their interaction
has been linked to localized testosterone secretion, independent
of LH release [9–12], bypassing the central dogma of
testosterone regulation.
A second form of GnRH, GNRH2, has also been identified
[13], and its structure remains completely conserved through-
out 500 million years of evolution [14], suggesting high
selection pressure and, therefore, a critical function [15]. Like
GNRH1, GNRH2 is a decapeptide but contains 3 amino acid
substitutions (His5, Trp7, Tyr8) compared to GNRH1 [13].
Uniquely, GNRH2 is expressed most highly in tissues outside
of the brain [16], suggesting a divergent role from GNRH1
[17]. Logically, GNRH2 has been examined for a role in
gonadotropin secretion. Indeed, GNRH2 stimulates LH release,
but with approximately 10% of the efficacy of GNRH1 [18],
which is consistent with a report showing that GNRH2 can
bind GNRHR1 with 10-fold less affinity than GNRH1 [19].
Primary cultures of porcine anterior pituitary cells release LH
and FSH in response to GNRH2 [20], but this effect was
attenuated with a GNRHR1 antagonist [21]. Thus, it is now
postulated that only high doses (e.g., 10 lg) of GNRH2 can
stimulate low levels of gonadotropin secretion through
GNRHR1 in vivo and in vitro [22–25].
A receptor specific to GNRH2 (GNRHR2) has been
identified in mammals [26, 27]. Similar to its ligand, GNRHR2
mRNA is present in the brain, as well as in peripheral tissues
such as the testis [26, 27], suggesting an autocrine or paracrine
action [26]. Unlike most species [17], swine maintain the gene
sequence for a functional GNRHR2 [28]. Using cDNA from
pig pituitaries, the porcine GNRHR2 has been cloned and
sequenced, showing 90% homology with African green
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monkey GNRHR2 [21, 29]. This receptor is considered
functional, as GNRH2 stimulation of cells overexpressing
porcine GNRHR2 resulted in IP
3
production [20].
In mammals that produce both the ligand and the full-length
receptor (e.g., musk shrews and old world monkeys [17]),
GNRH2 and its receptor have been implicated in the interaction
between nutritional plane and reproductive behavior [30–32],
as well as feed intake [31, 33, 34]. Additionally, indirect
evidence suggests that GNRH2 and its receptor may regulate
porcine testicular function. For example, males immunized
against GNRH2 displayed reduced levels of testosterone
compared to controls, whereas LH levels remained unchanged
[35]. Moreover, secretion of testosterone was suppressed in
boars treated with a GNRHR1 antagonist (SB-75) despite
normal concentrations of LH [36]. Additionally, SB-75
attenuated human chorionic gonadotropin (hCG)-stimulated
testosterone secretion in porcine testicular explant cultures
[36]. Given that GNRHR1 was not detected in swine testis
[36], it was postulated that a different mechanism must govern
localized testosterone release in swine [36]. Because others
have reported that high concentrations of SB-75 can bind to the
GNRHR2 in vitro [37], we hypothesized that the results of the
latter study could be ascribed to the interaction between SB-75
and GNRHR2 in porcine testes. Therefore, we sought to
examine the biological function of GNRH2 and its receptor in
the boar testis.
MATERIALS AND METHODS
Ethics
All animal procedures were conducted using standard production and
experimental practices in accordance with the Guide for the Care and Use of
Agricultural Animals in Research and Teaching [38] and were approved by
University of Nebraska-Lincoln (UNL) Institutional Animal Care and Use
Committee and by the US Meat Animal Research Center (USMARC). All
animals were individually housed with water available ad libitum and fed
approximately 2.5 kg daily.
GNRH2 and GNRHR2 Localization
Animals. Mature Chinese Meishan boars (n ¼ 7) from USMARC (Clay
Center, NE) were used. After exsanguination, the hypothalamus, anterior
pituitary gland, and testis were collected. Tissue samples (100 mg) were either
snap frozen and stored at 808C or fixed in 15 ml of 4% paraformaldehyde
(testis samples only).
Antisera. A goat polyclonal antibody directed against GNRHR2 (sc-
162889; lot B0810; Santa Cruz Biotechnology, Santa Cruz, CA) was used. This
antibody was prepared against a synthetic human peptide derived between
amino acids 60 and 75 of GNRHR2, representing the first N-terminal,
intracellular domain. It was determined by NCBI protein Basic Local
Alignment Search Tool (BLAST) that the epitope maintained 85% homology
for porcine GNRHR2, specifically the 7-transmembrane isoform (NCBI
accession number AAS68622.1). Moreover, the specificity of this antibody
was confirmed in our laboratory (data not shown).
A rabbit polyclonal antibody directed against prepro-GNRH2 (sc-20942; lot
C2403; Santa Cruz Biotechnology) was used. This antibody was prepared
against a synthetic human peptide derived between amino acids 1 and 120 of
prepro-GNRH2. It was determined by using protein BLAST that the epitope
maintained 45% homology for porcine prepro-GNRH2 and 100% homology
for the mature form of porcine GNRH2 (NCBI accession number
XP_005672842). Use of this antibody has been previously reported [39] to
detect GNRH2 in normal and human ovarian cancer cells. Furthermore, we
performed several antibody validation procedures in our laboratory (data not
shown).
Immunoblotting. Protein was extracted from samples of testis and
anterior pituitary gland (n ¼ 5) by homogenization in 1 ml of radioimmu-
noprecipitation assay buffer (20 mM Tris, 137 mM NaCl, 10% glycerol, 1%
NP-40, 0.1% SDS, 0.5% deoxycholic acid, 2 mM EDTA, 1 mM PMSF, 1%
protease inhibitor cocktail, and 1% phosphatase inhibitor cocktail) per 100 mg
of tissue with a Tissue-Tearor (Biospec, Bartlesville, OK). Protein
concentrations of all lysates were quantified using a bicinchoninic acid
(BCA) assay (Pierce Biotechnology, Rockford, IL) according to the
manufacturer’s instructions. Extracted protein was mixed with 43 loading
dye (2% Tris [pH 6.8], 28% glycerol, 20% SDS, and Orange G) containing
100 mM dithiothreitol. Then, 20 lg of testis protein was separated using SDS-
PAGE (10%) and transferred electrophoretically to a polyvinylidene
difluoride membrane (Immobilon-FL; Millipore, Billerica, MA). After
transfer, nonspecific binding was blocked by incubation (Odyssey blocking
buffer; LI-COR Biosciences, Lincoln, NE) for 1 h at room temperature (RT).
Membranes were then incubated with goat polyclonal primary antibody
directed against GNRHR2 (1:1000 dilution; sc-162889; Santa Cruz
Biotechnology), diluted in blocking buffer (Odyssey) with 0.05% Tween-20
and shaking at 48C, overnight. Membranes were next incubated with a
secondary donkey anti-goat antibody (1:16 000 dilution; IRDye 680; LI-COR
Biosciences) in blocking buffer (Odyssey) plus 0.05% Tween-20 and 0.025%
SDS for 1 h at RT. Between each step, membranes were washed in Tris-
buffered saline with 0.05% Tween-20 (TBS-T). Immunoblots were visualized
with a scanner (Odyssey) and image software (LI-COR Biosciences). Blots
were stripped in 13 stripping buffer (NewBlot; LI-COR Biosciences) for 30
min at 378C and reprobed with b-actin (1:2000 dilution; sc-1516; Santa Cruz
Biotechnology) to serve as a loading control.
Immunohistochemistry. After overnight fixation at 48C, testis samples
were dehydrated with 100% ethanol, cleared with CitriSolv (Fisher Scientific,
Pittsburgh, PA), embedded in paraffin, sectioned (7 lm), and mounted on slides
(UltraStick; Gold Seal Products, Portsmouth, NH). Epitope retrieval was
achieved by boiling slides in 0.01 M sodium citrate (pH 6.0) for 15 min.
Nonspecific binding was blocked with 10% rabbit serum for 20 min, and slides
were incubated for 30 min at RT with anti-GNRHR2 diluted 1:100 in 13 TBS
(25 mM Tris, 150 mM NaCl, 2 mM KCl). Alkaline phosphatase detection was
performed using a commercial kit (Vectastain; ABC-AP; Vector Blue; Vector
Laboratories, Burlingame, CA) according to the manufacturer’s instructions.
Slides were mounted with Tris-buffered 80% glycerol and imaged using an
Olympus microscope (model BX51; Center Valley, PA) and camera (model
DP71).
Immunofluorescence. Slide preparation was performed as described
above. Nonspecific binding was blocked with 10% goat serum (in TBS) for 1
h, and slides were incubated with an antibody directed against prepro-
GNRH2, diluted 1:50 in 10% normal goat serum at 48C overnight. Primary
antibody was centrifuged (10 000 3 g) for 10 min at 48C to avoid antibody
aggregates prior to use. Slides were rinsed 3 times in TBS-T (0.05% Tween-
20) for 5 min. Slides were washed in TBS-T and incubated with Alexa Fluor
555-labeled goat anti-rabbit secondary antibody (1:400 dilution; 4413; Cell
Signaling, Danvers, MA) for 1 h. Slides were then washed 3 times in TBS-T
and incubated with 0.3% Sudan Black B (Fisher Scientific) in 70% ethanol for
10 min at RT to reduce autofluorescence [40]. Slides were washed 3 times in
TBS-T and mounted with Tris-buffered 80% glycerol before sealing. Slides
were imaged using an inverted confocal microscope (model IX 81; Olympus)
with a TRITC filter set at the UNL Microscopy Core Facility (Lincoln, NE).
Enzyme-linked immunosorbent assay. Hypothalamus, anterior pituitary
gland, and testicular tissue samples were homogenized and assayed according
to the manufacturer’s instructions for a precursor form of GNRH2 with a
commercially available ELISA specific to the pig (CSB-EL009636PI;
Cusabio, Hubei, China). The primary antibody also has a high homology
with the mature decapeptide (Cusabio, personal communication). Optical
density was determined using a Wallac model 1420 Victor2 microplate reader
(Perkin-Elmer, Waltham, MA) at 450 nm. The minimum sensitivity of the
assay was 20 pg/ml, and the intra-assay coefficient of variation (CV) was
9.2%.
Ex Vivo Testicular Cultures
Animals. Mature Chinese Meishan boars (n ¼ 7) were euthanized, and
whole testes were collected. Testicular explant cultures were performed as
described by Zanella et al. [36]. Approximately 400 mg of finely minced
parenchymal tissue was incubated in 5 ml of TC199 (with Earle salts and
NaHCO
3
; Sigma-Aldrich, St. Louis, MO) buffered with a final concentration of
25 mM Hepes. Tissue was incubated in an atmosphere of 5% CO
2
in air at 378C
for 2 h. Preincubation was necessary because testosterone is released from the
tissue during dissection and can mask hormone-induced testosterone secretion
[41]. Media were decanted and replaced with fresh TC199, and explants were
randomly assigned to treatment.
Treatments. Samples of media (250 ll) were collected to assess basal
hormone levels (time 0). After media collection, explant cultures were exposed
to either 30 ll of vehicle (water) or 1 lMGNRH2 (Bachem Inc., Torrance, CA)
as a pretreatment. These doses were determined based on the work of Zanella et
al. [36] and Darby et al. [42]. Media (250 ll) samples were collected 1 h after
pretreatment from all cultures, and explants were treated with either 30 ll of
vehicle (water) or 1 IU of hCG (Sigma-Aldrich). Therefore, four combinations
DESAULNIERS ET AL.
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(pretreatment þ treatment) were tested, as follows: control (vehicle þ vehicle),
hCG alone (vehicle þ hCG), GNRH2 pretreatment without hCG (GNRH2 þ
vehicle), and GNRH2 pretreatment with hCG (GNRH2 þ hCG). Media (250
ll) were collected at 120, 180, and 240 min after treatment, frozen immediately,
and stored at208C until quantification of testosterone with radioimmunoassay
(RIA).
In Vivo Boar Trials
Catheterization. Trial 1 was conducted at USMARC, using mature
Chinese Meishan boars, whereas Trials 2 and 3 were performed at UNL Animal
Science Building with mature white crossbred boars obtained from the UNL
Agricultural Research and Development Center (ARDC) swine unit (Mead,
NE). Catheterization of boars was conducted according to either Ford and
Maurer [43] or Barb et al. [44] approximately 4 days prior to initiation of
experimentation. All in vivo experiments were conducted in a crossover design,
where each boar received the opposite treatment 1 week later.
Peptides. Both D-ala6 GnRH-I (Bachem Inc.) and D-ala6 GnRH-II (Anygen,
Gwangju, Korea) were dissolved in 0.9% sterile saline. SB-75 was synthesized
by the UNL Protein Core Facility (Lincoln, NE) and dissolved in 0.9% sterile
saline. Trptorelix-1 (Trp-1; Anygen) was dissolved according to the
manufacturer’s instructions. Briefly, Trp-1 was first dissolved in 5%
dimethylacetamide, mixed with 40% propylene glycol, and finally, diluted in
55% water.
Trial 1. Prior to treatment, blood samples were collected in plasma blood
tubes (KMO-EDTA; S-Monovette; Sarstedt, Nu¨mbrecht, Germany) every 20
min for 2 h to obtain a baseline hormone profile (120 to 0 min). Boars were
then given a bolus infusion (i.v.) of either a GNRHR1 (D-ala6 GnRH-I; 150 ng/
kg body weight [BW], n¼ 8) or GNRHR2 (D-ala6 GnRH-II; 150 ng/kg BW, n
¼ 6) agonist in approximately 2 ml of saline (0 min). Blood samples were
drawn every 10 min for 30 min and every 20 min for 270 min thereafter. Blood
samples remained at 48C until centrifugation (2000 3 g), and plasma was
collected and stored at 208C until RIA.
Trial 2. Blood was collected in sera tubes (KMO-SER; Sarstedt) at 20 and
10 min and immediately prior to injection to quantify basal hormone levels.
Boars then received a dose (1 ml of saline, i.m.) of the GNRHR1 antagonist
SB-75 (5 lg of biologically active compound/kg BW). Based on preliminary
trials, blood was collected 7.5 h later, and then boars were given a bolus
infusion (i.v.) of either GNRHR1 (D-ala6 GnRH-I; 150 ng/kg BW, n ¼ 5) or
GNRHR2 (D-ala6 GnRH-II; 150 ng/kg BW, n¼ 5) agonist in approximately 2
ml of saline. Blood samples were drawn every 10 min for 30 min and then
every 20 min for 270 min after agonist treatment. Blood samples remained at
48C until centrifugation (2000 3 g), and serum was collected and stored at
208C until RIA.
Trial 3. Prior to treatment, blood was drawn at 30 min and immediately
prior to analog administration. Treatment with either GNRHR1 (SB-75; 5 lg of
biologically active compound/kg BW, n¼9) or GNRHR2 (Trp-1; 5 lg/kg BW;
n¼ 10) antagonist were given i.m. Each animal also received the vehicle of the
opposite treatment (i.m.). Blood sampling occurred every 30 min for 3 h (30,
60, 90, 120, 150, and 180 min) and at 6, 12, 24, 36, and 48 h after treatment.
Blood samples remained at 48C until centrifugation (20003 g), and serum was
collected and stored at 208C until RIA.
Radioimmunoassay. Total testosterone concentrations from explant
medium samples were determined using a total testosterone Coat-a-Count
RIA kit (Siemens Healthcare Diagnostics, Los Angeles, CA) in accordance
with the manufacturer’s instructions. This kit has been previously validated
in the pig [45, 46]. The minimum sensitivity of the assay was 0.16 ng/ml.
Inter- and intra-assay coefficients of variation (CVs) were 4.3 and 4.6%,
respectively. Testicular explant medium samples were diluted 1:5 with a
zero calibrator solution (0 ng/ml testosterone; Siemens Healthcare
Diagnostics) in order to fit the standard curve, according to the
manufacturer’s instructions.
Plasma samples from Trial 1 were assayed for testosterone in duplicate
according to Ford et al. [47]. The minimum sensitivity of the assay was 50
pg/ml, and the intra- and inter-assay CVs were 7% and 12.9%, respectively.
In Trials 2 and 3, total testosterone concentrations in boar sera were
measured in duplicate using a total testosterone Coat-a-Count RIA kit
(Siemens Healthcare Diagnostics) according to the manufacturer’s instruc-
tions. However, 2 additional standards were added to increase the sensitivity
of the curve (0.04 and 0.08 ng/ml; per manufacturer’s instruction), therefore
the minimum sensitivity of the assay was 0.04 ng/ml. The average intra- and
inter-assay CVs were 6.2 and 8.5%, respectively. LH concentrations for all
trials were determined at USMARC in duplicate according to Kesner et al.
[48]. The minimum sensitivity of the assay was 0.1 ng/ml. Pools of porcine
serum with LH concentrations that ranged from 0.23 to 6.0 ng/ml were
included in each assay (n ¼ 9). Intra- and inter-assay CVs were 9.9 and
12%, respectively.
Statistical Analysis
Statistical analyses were performed using the Statistical Analysis System
(SAS, Cary, NC). All data were examined for normality using the Shapiro-Wilk
test prior to analysis. Data that did not meet normality assumptions were log
transformed, analyzed, and back-transformed to the original scale for
interpretation. Western blots and ELISA data were analyzed using the general
linear model procedures of SAS with animal as the experimental unit and tissue
type as the fixed effect. Explant RIA data were analyzed using the MIXED
procedure of SAS with time included in the model as a repeated measure and
assay as a random effect. Data were first normalized to pretreatment hormone
levels and then expressed as fold-change over values for the control (vehicle þ
vehicle) within animal.
Results from in vivo Trials 1 to 3 were analyzed with the MIXED
procedure of SAS, using a statistical model that included day, treatment,
time, and the interaction of treatment with time as fixed effects. Time was
used as the repeated measure with boar 3 treatment 3 day as the subject.
Preinjection concentrations of hormone were used as the covariate. Degrees
of freedom for the pooled error term were calculated using the Satterthwaite
approximation. Based on Akaike information criterion, a first-order
autoregressive or heterogeneous autoregressive function with lag equal to 1
was used to model the covariance structure for the repeated measures. When
a significant (P  0.05) main effect was observed, pair-wise comparisons
were made using the Tukey-Kramer test adjusted for the degrees of freedom
in the covariance matrix. Results are presented as means 6 standard errors of
the mean (SEM).
RESULTS
GNRH2 and Its Receptor Are Abundantly Expressed in the
Testis
Presence of GNRHR2 in the testis and anterior pituitary
gland was confirmed via Western blot analysis using an anti-
GNRHR2 antibody (Fig. 1A). Quantification of relative band
density indicated that the testis contained 6-fold higher
amounts of GNRHR2 protein than the anterior pituitary gland
(P , 0.0001) (Fig. 1B). Given this discovery, we examined
the levels of GNRH2 in homogenates from the hypothalamus,
anterior pituitary gland, and testis via ELISA. The concen-
tration of GNRH2 protein was significantly elevated in the
testis (P , 0.0001) compared to that in the anterior pituitary
FIG. 1. GNRHR2 protein levels are significantly higher in the testis than
in anterior pituitary gland. Representative Western blot of porcine anterior
pituitary gland and testicular tissue (n ¼ 5), using an antibody directed
against GNRHR2 (A). Quantification of immunoblots revealed differences
in GNRHR2 protein levels between tissue types (*P , 0.0001) (B).
GNRH2 AND GNRHR2 IN THE TESTIS
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gland or hypothalamus, which had similar values (P . 0.05)
(Fig. 2).
GNRH2 Localizes Primarily to the Tubular Compartment,
Whereas GNRHR2 Is Expressed in Both the Interstitial and
Tubular Compartments
Immunohistochemistry of testicular tissue using a
GNRHR2 antibody revealed immunoreactivity within the
interstitial compartment, as well as within the seminiferous
tubules (Fig. 3, B–D). However, GNRHR2 signal appeared
most prominent in the interstitial compartment. Within the
interstitium, staining appeared to localize to Leydig cells,
based upon location and morphology, with both intracellular
and peripheral signal (Fig. 3D). Immunostaining was also
visible within the seminiferous tubules and appeared localized
to germ cells and Sertoli cells (Fig. 3D). In contrast, there was
no signal detected in control sections incubated without the
primary antibody (Fig. 3A). Based on these results, we next
localized GNRH2 within testicular sections using immuno-
fluorescence. GNRH2 immunostaining appeared primarily
within the tubular compartment (Fig. 4, A–C), localizing to
germ cells (Fig. 4, D–F). In contrast, no fluorescence signal
was detected in sections processed without the primary
antibody (Fig. 4, A–C insets).
GNRH2 Alone Stimulates Testosterone Secretion in
Testicular Explant Cultures
Based on our immunohistochemistry results, we examined
the effects of GNRH2 on steroidogenesis. There was no effect
of time or treatment 3 time interaction for fold-change in
testosterone concentration, so these effects were removed
from the statistical model. We observed an effect of treatment,
as treatment with either hCG or GNRH2 increased testoster-
one secretion compared to treatment with vehicle (P , 0.001)
(Fig. 5). Release of testosterone from testicular explants
receiving GNRH2 pretreatment was not different than
explants receiving vehicle pretreatment followed by hCG (P
. 0.05) (Fig. 5). Moreover, pretreatment with GNRH2 did
not further enhance hCG-induced testosterone secretion
compared with that of explant cultures receiving pretreatment
with saline before hCG treatment (P . 0.05) (Fig. 5).
GNRH2 and GNRH1 Stimulate Testosterone Secretion
Similarly Despite Differences in LH Release
To further evaluate the effect of GNRH2 on testosterone
secretion, we treated boars with either D-ala6 GnRH-I or D-ala6
GnRH-II. We observed a treatment3 time effect (P , 0.003)
for change in LH concentrations (Fig. 6A). Within 10 min after
administration of GNRH1, LH concentrations increased over
FIG. 2. GNRH2 levels are higher in tissue homogenates from the testis
than in the hypothalamus or anterior pituitary gland. GNRH2 levels were
determined by ELISA in homogenates from the hypothalamus, anterior
pituitary gland, and testis of boars (n ¼ 6). a,b Bars with alternate letters
differ (P , 0.0001).
FIG. 3. GNRHR2 localizes to both the tubular and the interstitial compartments of the testis. Representative immunohistochemistry image of porcine
testes (n¼7), using an antibody directed against GNRHR2 (B–D) compared to the negative control (A). Original magnification3200 control (A);3200 (B),
3400 (C),31000 under oil immersion (D).
DESAULNIERS ET AL.
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pretreatment amounts, reached maximal levels by 130 min, and
remained elevated for the duration of sampling (Fig. 6A, 270
min). In contrast, LH levels increased within 10 min following
GNRH2 treatment but steadily declined to pretreatment values
by 50 min (Fig. 6A).
Unlike LH secretion, we did not observe a treatment3 time
interaction or an effect of treatment for change in testosterone
levels after GNRH1 or GNRH2 treatment (P. 0.05) (Fig. 6B).
We also observed a significant effect of time (P , 0.0001)
(Fig. 6B), indicating that treatment with GNRH1 or GNRH2
altered testosterone secretion over time. Thus, both treatments
stimulated a similar increase in testosterone secretion (P .
0.05) during the sampling period.
Pretreatment with SB-75 Inhibits GNRH2-Mediated
Testosterone Secretion
Next, we evaluated whether the recognized GNRHR1
antagonist, SB-75, interfered with testicular GNRHR2 func-
tion. We observed a treatment 3 time effect for the LH
response (P , 0.001) (Fig. 7A). After administration of the
GNRHR1 antagonist, SB-75, concentrations of LH tended to
be reduced in both the GNRH1 and the GNRH2 treatment
groups compared with pretreatment concentrations of LH (P ,
0.10) (Fig. 7A). After treatment with GNRH1, LH levels rose
significantly above pretreatment levels within 10 min and
remained elevated for 50 min before returning to basal levels
for the remainder of the sampling period (270 min). In contrast,
after treatment with GNRH2, serum LH concentrations were
not significantly stimulated over time compared to basal
hormone levels (P . 0.05) (Fig. 7A). Compared to post-SB-75
hormone concentrations, GNRH1 treatment stimulated LH
secretion within 10 min, remaining elevated through 190 min.
In contrast, GNRH2 treatment stimulated LH secretion over
post-SB-75 levels at 10, 20, and 30 min before returning to
basal concentrations (Fig. 7A).
For the testosterone response, we observed a tendency for a
treatment3 time interaction (P , 0.10). After treatment with
SB-75, testosterone levels dropped below pretreatment
concentrations at time 0 and remained suppressed (P ,
0.05) after treatment with GNRH1 through 20 min post
treatment before returning to baseline. Similarly, testosterone
was suppressed below basal levels 7.5 h after SB-75 treatment
(time 0) and remained reduced 10, 20, and 30 min post
treatment in animals that received GNRH2. At 90 and 110
min, testosterone levels were elevated over baseline values in
GNRH1-treated animals (P , 0.05), whereas GNRH2
treatment was unable to induce testosterone concentrations
above basal levels (P . 0.05) at any time point. Compared to
post-SB75 concentrations (time 0), testosterone was greater
from 50 to 210 min following GNRH1 administration (P ,
0.05) and from 50 to 150 min in GNRH2-treated animals (P
, 0.05), with 170 min tending to be greater than time 0 (P ,
0.10).
LH and Testosterone Secretion Are Reduced after
Treatment with GNRHR1 Antagonist SB-75 but Not with
GNRHR2 Antagonist Trp-1
To further examine the effect of receptor antagonism, we
compared a GNRHR2-specific antagonist, Trp-1 [49, 50], with
the GNRHR1 antagonist, SB-75. For change in LH levels,
FIG. 4. GNRH2 is localized primarily to the tubular compartment of the testis. Representative immunofluorescence image of porcine testes (n¼5), using
an antibody directed against GNRH2; (A, D) fluorescence; (B, E) transmitted light; (C, F) merge of fluorescence and transmitted light. A–C) Insets are
sections incubated without primary antibody: (A) fluorescence, (B) transmitted light; (C) merge of fluorescence and transmitted light. Original
magnification3200 (A–C);3400 (D–F).
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there was no treatment 3 time interaction (P . 0.05) or an
effect of treatment (P . 0.05) (Fig. 8A). However, there was
an effect of time (P , 0.0001) (Fig. 8A). Specifically, LH
concentrations were suppressed compared to basal levels at 2.5,
3, 6, and 12 h after SB-75 treatment (P , 0.05). In contrast,
Trp-1 treatment did not reduce LH secretion at any time point
compared to basal levels (P . 0.05).
We observed a treatment3 time interaction (P , 0.04) for
change in testosterone concentrations (Fig. 8B). After treatment
with SB-75, serum testosterone levels were significantly
reduced at 2.5, 3, 6, and 12 h compared with pretreatment
values (P , 0.05) (Fig. 8B). After administration of Trp-1,
serum testosterone concentrations were unaffected over time (P
. 0.05).
DISCUSSION
Despite identification of mammalian GNRHR2 in 2001 [26,
27], the role of this novel receptor has been elusive [25].
However, complete conservation of the ligand sequence and
presence of a functional receptor gene in just a few mammalian
species [51] indicates an important biological function [17].
Thus far, most mammalian studies have examined the
interaction between GNRH2 and its receptor as it relates to
nutrition and reproductive behavior of old world monkeys and
musk shrews [30–34, 52–54]. In fact, only a handful of studies
have examined the porcine GNRHR2 gene [21, 28, 29] or
functionality (IP
3
and LH production) of the receptor in vitro
[20]. Although these reports indicated that the porcine
GNRHR2 was functional, they did not divulge a biological
FIG. 5. GNRH2 directly stimulates testosterone production from ex vivo
testicular cultures. Relative testosterone levels secreted by testicular
explant cultures (n ¼ 7) pretreated with or without GNRH2, followed by
treatment with vehicle or hCG. a,b Bars with alternate superscripts differ (P
, 0.001).
FIG. 6. GNRH2 and GNRH1 stimulate testosterone production similarly
despite reducedGNRH2-induced LH secretion. Least squaresmeans (6SEM)
plasma concentrations of LH (A) and testosterone (B) after intravenous
administration of D-ala6 GnRH-I (solid line) or D-ala6 GnRH-II (dotted line).
After pretreatment sampling (120 to 0 min), treatments were administered
(0min [arrow]). For LH, treatment,P, 0.001. Time, P, 0.0001. Treatment3
time, P , 0.03. For testosterone, treatment, P¼ 0.1929. Time, P , 0.002.
Treatment 3 time, P ¼ 0.7190. *Within treatment, concentrations are
different frompreinjection concentrations; P, 0.05. GNRH1 differences are
above error bars, and GNRH2 differences are below error bars.
FIG. 7. GNRHR1 antagonist pretreatment mitigates GNRH2-mediated
testosterone production. Least squares means (6SEM) serum concentra-
tions of LH (A) and testosterone (B) after intramuscular administration of
the GNRHR1 antagonist SB-75 at 7.5 h prior to intravenous treatment with
D-ala6 GnRH-I (solid line) or D-ala6 GnRH-II (dotted line). After
pretreatment sampling, SB-75 was administered (black arrow). Approxi-
mately 7.5 h later, blood was collected, and treatments were administered
(0 min [gray arrow]). For LH, treatment, P , 0.0001. Time, P , 0.0001.
Treatment 3 time, P , 0.005. For testosterone, treatment, P ¼ 0.1100.
Time, P , 0.0001. Treatment 3 time, P , 0.10. *Within treatment,
concentrations are different from preinjection concentrations; P , 0.05.
8Within treatment, concentrations are different from post-SB-75 concen-
trations (0 min); P, 0.05. Within treatment, concentrations tend to differ
from preinjection concentrations; P, 0.10. GNRH1 differences are above
error bars and GNRH2 differences are below error bars.
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role for GNRHR2 in pigs. As swine are one of the few
mammalian species to maintain both the ligand and the
functional receptor [28], we sought to examine the role of
GNRH2 and its receptor in the reproductive physiology of pigs.
Evidence for GNRHR2 mRNA in the anterior pituitary
gland and testis has been reported previously in humans [26]
and marmosets [27], but this is the first report of GNRHR2
protein in porcine tissues. Given the ubiquitous expression of
GNRHR2 [26, 27], the presence of this receptor in the anterior
pituitary gland and testis of the boar may not be surprising;
however, quantitation of Western blots revealed GNRHR2
levels were greater in the testis than the anterior pituitary gland.
Similarly, Millar et al. [27] demonstrated that the marmoset
testis expressed the greatest amount of GNRHR2 mRNA
compared to any other tissue, including the anterior pituitary
gland. Additionally, we detected prepro-GNRH2 in porcine
tissue homogenates of the hypothalamus, anterior pituitary
gland, and testis. Indeed, GnRH2 (mRNA or protein) has been
detected in the hypothalamus [13, 16, 55], pituitary [16, 56],
and testis [16, 57] of other species; however, this is the first
report of GNRH2 production in pig tissues. Moreover, relative
concentrations of prepro-GNRH2 in tissue homogenates have
not been quantitated in other species. Concentrations of
GNRH2 were greater in the testis than in the hypothalamus
or anterior pituitary gland, suggesting a functional significance
in porcine testis biology.
Here, we report immunoreactive staining for GNRH2 and its
receptor in the swine testis. Interestingly, GNRH2 and
GNRHR2 immunostaining was most intense within the tubular
and interstitial compartments, respectively. Although little
GNRH2 staining was detected in the interstitium, this may be a
consequence of the ligand being bound to its receptor or loss of
the secreted decapeptide during tissue processing. Neverthe-
less, it appears GNRH2 and its receptor may interact in a
paracrine manner within the porcine testis. Notably, we
detected intense GNRHR2 immunostaining within the intersti-
tial compartment, localizing to Leydig cells. Logically, the
identification of GNRHR2 on Leydig cells may indicate a
potential role in steroidogenesis. This discovery, coupled with
previous literature [35, 36], prompted us to directly test if
GNRH2 alone could elicit testosterone secretion in explant
cultures of testicular tissue from boars.
We demonstrated that ex vivo testicular explants secreted
testosterone after stimulation with hCG, a finding consistent
with those of previous studies [36, 58]. Notably, we observed
that short-term treatment with GNRH2 stimulated testosterone
release similar to treatment with hCG, indicating that GNRH2
is a direct stimulator of testosterone secretion within the testis.
However, pretreatment with GNRH2 before hCG treatment did
not elicit a synergistic release of testosterone, suggesting that
GNRH2 is not priming LH receptor activity. Therefore, it
appears that GNRH2 alone is sufficient to stimulate testoster-
one secretion in vitro. These results have precedent in species
which maintain a testicular GNRHR1. Recall that GNRH1 and
its receptor have been implicated in localized testosterone
release [11, 12, 59] as the GNRHR1 has been identified on
Leydig cells in other species [60–65]. Given that the GNRHR1
could not be isolated in porcine testis [36], the testicular
GNRH2-GNRHR2 system present in pigs might function in
lieu of the GNRH1-GNRHR1 system.
Based on these data, we next examined the effect of
GNRH2 treatment in vivo. In the present study, males
challenged with GNRH1 and GNRH2 demonstrated differen-
tial LH secretion over time. Of course, it is well known that
GNRH1 stimulates LH production in the boar [66]. Addition-
ally, high doses of GNRH2 stimulate low levels of LH
secretion in other species [67]. However, this effect is likely
mediated through the interaction between GNRH2 and
GNRHR1. In the current study, LH was only transiently
elevated in GNRH2 compared to GNRH1 treated boars,
indicating that GNRH2 activated GNRHR1 within the anterior
pituitary gland. Despite lower LH levels, testosterone concen-
trations in males treated with GNRH2 mirrored levels seen in
GNRH1-treated animals. These results suggest that GNRH2
elicited testosterone secretion directly at the level of the testis,
likely via interaction with its cognate receptor on Leydig cells.
In the next trial, we wanted to determine whether SB-75, an
established GNRHR1 antagonist, impacted testicular GNRHR2
function, by pretreating boars with SB-75 prior to infusion with
GNRH1 or GNRH2. The secretory patterns of LH following
GNRH1 and GNRH2 treatment (Fig. 7A) were similar to the
results from Trial 1 (Fig. 6A), confirming that GNRH2 is an
ineffective stimulator of LH release in the boar. Furthermore,
GNRH2 treatment restored testosterone levels from suppres-
sion after administration of SB-75 but to a lesser extent than
GNRH1. These results for GNRH1- and GNRH2-induced
testosterone secretion differed from testosterone profiles
observed in Trial 1 (Fig. 6B). This discrepancy between
GNRH1- and GNRH2-stimulated testosterone secretion in
Trial 2 (Fig. 7B) compared to that in Trial 1 (Fig. 6B) could be
due to the reduced levels of LH secretion stimulated by
GNRH2 (Fig. 7A). However, the secretory patterns of LH from
FIG. 8. The GNRHR1 antagonist SB-75 but not the GNRHR2 antagonist
Trp-1 reduces serum LH and testosterone concentrations. Least squares
means (6SEM) serum concentrations of LH (A) and testosterone (B) after
intramuscular administration of a GNRHR1 (SB-75 [solid line]) or
GNRHR2 (Trp-1 [dotted line]) antagonist. After pretreatment (30 to 0
min) sampling, treatments were administered (0 min [arrow]). For LH,
treatment, P¼ 0.2644. Time, P , 0.0001. Treatment3 time, P¼ 0.2220.
For testosterone, treatment, P ¼ 0.2923. Time, P , 0.0001. Treatment 3
time, P , 0.04. *Within the SB-75 treatment, concentrations are different
from preinjection levels; P , 0.05 (below error bars).
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Trials 1 (Fig. 6A) and 2 (Fig. 7A) appeared quite similar;
suggesting that the GNRH2-induced LH secretion observed in
Trial 2 (Fig. 7A) should be sufficient to stimulate testosterone
secretion similar to GNRH1. Thus, we focused on the major
differences between Trials 1 and 2, which was the adminis-
tration of SB-75. SB-75 has been reported to bind GNRHR2 in
cell culture experiments [49]. If SB-75 bound to GNRHR2
within the testis, the GNRHR2 agonist would have been
ineffective at eliciting testosterone secretion. This is consistent
with data from Zanella et al. [36] who demonstrated that SB-75
can effectively inhibit porcine testicular GNRHRs. Moreover,
the affinity of SB-75 for the GNRHR2 is not yet defined in the
literature. Therefore, our data suggest that SB-75 can interact
with the sole GNRHR present within the boar testis, the
GNRHR2, to inhibit GNRH2-stimulated testosterone secretion.
In our last experiment, treatment with SB-75 suppressed LH
and testosterone concentrations, consistent with other reports
[68, 69]. Compared to pretreatment levels, however, neither
LH nor testosterone concentrations were significantly reduced
by Trp-1 treatment at any time points examined. The limited
inhibition of testosterone following Trp-1 treatment contradicts
the potent stimulatory effect of GNRH2 on testosterone release
observed in Trial 1 (Fig. 6B). To our knowledge, this is the first
experiment examining the in vivo effects of Trp-1 on endocrine
function, as previous reports have examined the actions of Trp-
1 as a prostate cancer treatment in immortalized cell lines and
tumors in nude mice [37, 50, 70]. We used a dose of SB-75 (5
lg/kg BW) previously reported to be effective at suppressing
LH and testosterone release in boars [71] and chose to use the
same amount of Trp-1. Perhaps the level of Trp-1 used was
insufficient to fully antagonize the GNRHR2 or the vehicle
used (5% dimethylacetamide, 40% propylene glycol, 55%
water) released Trp-1 in a different manner than the saline
vehicle used for SB-75. Therefore, further investigation into
the biological action of Trp-1 on endocrine function is merited.
To conclude, these data confirm that the pig transcribes the
GNRHR2 gene into a functional protein. Moreover, we
discovered that boars maintain a unique testicular GNRH2-
GNRHR2 system. Here, we provide evidence for functionality
of the GNRHR2 in vitro and in vivo. Our data suggest that
GNRH2 is produced locally in the testis for interaction with its
receptor. Given the identification of the GNRHR2 on Leydig
cells in this study, we propose that GNRH2 and its receptor
may function together to mediate localized testosterone
secretion in the porcine testis.
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